Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen After ASCO: Questions Remain On Lumakras, Bemarituzumab

Executive Summary

Remaining questions after ASCO include whether Lumakras (sotorasib) might work in first-line NSCLC with certain co-mutations and if ocular toxicities will hamper bemarituzumab in gastric cancer.

You may also be interested in...



Keeping Track: New Uses For Opdivo, Trodelvy; Nextstellis Introduces A Novel Estrogen

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Amgen Paying $1.9bn For Five Prime And Its Gastric Cancer Antibody

Five Prime’s Phase III-ready bemarituzumab could offer significant revenue for Amgen, particularly in Asia, but analysts ask if the buyout is a precursor to greater deal making by Amgen.

Amgen’s KRAS G12C Inhibitor Shows Deep, Durable Efficacy In Lung Cancer

Results from the Phase II CodeBreak 100 study of sotorasib presented at the World Conference on Lung Cancer were included in Amgen’s applications for approvals in the US, EU and other countries. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144506

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel